Evidence map›Paper›PMID 25941355›Full record

ReviewCancer immunology research2015

The interplay of immunotherapy and chemotherapy: harnessing potential synergies.

Leisha A Emens, Gary Middleton

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 470 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
470citing papers in PubMed, 12 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04107103 phase2completednot on this mapstarted 2020, after this paper: background citation

A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck

TypeinterventionalSponsorAHS Cancer Control AlbertaRan2020 to 2023Enrolled6ConditionsSCCHNArmsCombination Product: Nivolumab with Pemetrexed
NCT06284746 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Clinical Efficacy and Safety of Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Resectable Gastric Cancer

TypeinterventionalSponsorLin ChenRan2023 to 2025Enrolled80ConditionsLocally Advanced Gastric Carcinoma, HER2 Negative, Efficacy, SafetyArmsTirolizumab+SOX/XELOX, SOX/XELOX
3 · Its place in the literature

Who cites it

470 citing papers in PubMed, 12 syntheses or guidelines pooled it, 804 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  19. Trial
  20. Trial

410 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Leisha A EmensDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland. Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland. emensle@jhmi.edu G.Middleton@bham.ac.uk.
Gary MiddletonCancer Immunology and Immunotherapy Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom. Department of Medical Oncology, University Hospital Birmingham, Birmingham, United Kingdom. emensle@jhmi.edu G.Middleton@bham.ac.uk.
Sidney Kimmel Cancer Center · US

Funding

CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENTK23CA098498 · NCI · JOHNS HOPKINS UNIVERSITY · PI EMENS, LEISHA A · 2003 to 2006
$554k
Summer Translational Oncology Program (STOP)R25CA171973 · NCI · JOHNS HOPKINS UNIVERSITY · PI BUNZ, FRED, EMENS, LEISHA A · 2013 to 2017
$340k
Cancer Research UKNCI NIH HHS K23 CA098498NCI NIH HHS R25 CA171973
6 · The paper itself

Abstract

Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted that certain chemotherapies can augment tumor immunity. The recent success of immune checkpoint inhibitors has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity. Two major ways that chemotherapy promotes tumor immunity are by inducing immunogenic cell death as part of its intended therapeutic effect and by disrupting strategies that tumors use to evade immune recognition. This second strategy, in particular, is dependent on the drug, its dose, and the schedule of chemotherapy administration in relation to antigen exposure or release. In this Cancer Immunology at the Crossroads article, we focus on cancer vaccines and immune checkpoint blockade as a forum for reviewing preclinical and clinical data demonstrating the interplay between immunotherapy and chemotherapy.

Indexed as

ImmunotherapyAnimalsAntineoplastic AgentsCancer VaccinesCombined Modality TherapyHumansNeoplasmsAntineoplastic AgentsCancer Vaccines

Identifiers

PMID25941355
PMCPMC5012642
OpenAlexW2079315541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.